SDM takes second place and $15,000 at LBS MENA Startup Competition

Saudi health-tech startup SDM has taken second place at the London Business School MENA Startup Competition 2026 and won $15,000. The final was held on 14 October in Dubai. The prize is non-dilutive and forms part of a $45,000 pool shared by the top three. UAE environmental startup Persium took first place. Frank AI, which builds an agent operating system for independent real-estate professionals across the GCC, took third. No valuation, no prior funding and no patient-volume figures were disclosed for SDM. SDM develops AI tools for early detection of chronic disease. Its first product, SAARIA, analyses one retinal image per eye captured on-site without pupil dilation. The images are processed in a Saudi-hosted cloud and a bilingual Arabic-English PDF report is generated within one minute. The company states sensitivity greater than 90 percent using international grading standards, and says a physician does not need to be physically present. The tool is aimed at diabetic eye screening in rural and underserved areas. SDM is also developing models for early risk indicators of hypertension, stroke and Alzheimer’s disease, and a separate product, SAMIA, for mammogram image analysis. Nearly 100 applications came from across MENA. Ten finalists pitched. Judges included Karim Hasab El-Nabi, Jane Khedair, Pier Armando Vender and Umer Saleem. SDM’s chief executive, Naif Al-Obaidallah, said the result was a proud moment and that the company would use the prize to expand operations and explore other healthcare applications. For a clinic in a smaller Saudi city the useful distinction is between a one-minute report and a specialist visit. A patient who previously had to travel for diabetic eye screening can now have an image taken locally and a report returned in a minute. Whether that report is accepted by the Ministry of Health or by insurers as a substitute for an ophthalmologist’s reading is not stated. The sensitivity figure is company-stated. No independent multi-center validation or regulatory approval number was published with the competition result. The $15,000 is a prize, not an investment round. It does not set a valuation and does not require equity. SDM can spend it on operations or on the next clinical study. The company has not said how the money will be allocated. A prize of this size can fund a small validation or a regulatory filing. It does not fund a national rollout. Other finalists included Saudi fintech NSBH. Three Saudi startups reached the top ten. The competition therefore showed both health and non-health companies from the Kingdom. The health result is a screening tool that shortens the path from image to report. It does not yet show how many patients have used it or how many referrals it has generated. A further limit is the clinical setting. SAARIA is designed for on-site capture without dilation. A rural clinic that has a suitable camera and a stable connection can run it. A clinic that lacks either cannot. The release does not say how many Saudi facilities already meet those conditions. Until that number is known, the access claim is technical, not geographic. The same constraint applies to the other conditions SDM is targeting. A model that flags early hypertension or Alzheimer’s risk still needs a pathway into existing care. The prize money can support the next study. It does not create the pathway. That work remains with the company and with the health system that would accept the reports. A clinic in the UAE or Qatar that already screens for diabetic eye disease can compare its current pathway with the one-minute report. Whether it would switch depends on regulatory acceptance and on cost. Neither figure is in the competition announcement. The announcement records a ranking and a prize. It does not record a deployment. The competition attracted founders from the UAE, Saudi Arabia, Kuwait, Egypt and Syria. SDM’s second place is one result inside that field. It does not rank the company against other Saudi health-tech firms that did not apply. If SDM publishes the number of SAARIA reports issued after the prize and any regulatory clearance obtained, the second-place finish has a clinical follow-on. If the next line is only another competition mention, count the reports that were acted on and the patients who did not need to travel. The figure missing is both.